Multicenter Real-World Outpatient Use of Intravenous Omadacycline

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Omadacycline is approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
• Limited real-world data exist on intravenous (IV) omadacycline use in outpatient settings for diverse infections.

Purpose of the Study:

• To evaluate the clinical experience and outcomes of IV omadacycline in an outpatient setting.
• To assess the safety and efficacy of omadacycline for various infections treated in infusion centers.

Main Methods:

• A multicenter, retrospective review of 67 adult patients receiving IV omadacycline between April 2019 and November 2022.
• Data collected included infection type, microbiology, therapy characteristics, and adverse events.
• Clinical success was defined as symptom resolution; 12-month recurrence data were assessed for bone and joint infections (BJI).

Main Results:

• The study included 67 patients, with BJI being the most common diagnosis (53.7%).
• Omadacycline achieved an 86.9% clinical success rate in evaluable patients.
• Sustained clinical success at 12 months was observed in 72.4% of BJI patients.

Conclusions:

• Intravenous omadacycline is safe and effective for treating various serious infections in the outpatient setting.
• The drug demonstrated efficacy in treating bone and joint infections and mycobacterial infections.
• Real-world data support the use of omadacycline in ambulatory infusion centers.